2021 IPO

Caribou Biosciences Stock

Biotechnology company specializing in genome engineering

Sign up today and learn more about Caribou Biosciences Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.



Notable Investors

F-Prime Capital Partners


Berkeley CA, US

Total Funding


About Caribou Biosciences Stock

Caribou Biosciences is a biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins.


Funding History

October 2014$2.9M
March 2015$11.5M
May 2016$30.0M
May 2016$30.1M



Jennifer A. Doudna


James Berger

Chief Scientific Officer

Andy May


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: